本文選題：阿侖膦酸鈉 + 膦酸類�。� 參考：《中國新藥與臨床雜志》2017年05期

【摘要】：目的研究阿侖膦酸鈉服藥間隔對骨質(zhì)疏松癥患者藥物治療依從性的影響。方法 164例患有骨質(zhì)疏松癥婦女隨機分為試驗組(n=83)接受阿侖膦酸鈉70 mg,2周1次治療,對照組(n=81)接受阿侖膦酸鈉70 mg,每周1次治療。觀察治療兩年的服藥順應性、服藥持續(xù)性和不良反應。以治療期間的藥物持有率(MPR)判斷患者服藥順應性,MPR≥80%為服藥有順應性;采用治療期間開始用藥至終止用藥的天數(shù)表達患者服藥持續(xù)性,停藥間隔超過30 d判斷為終止用藥,在治療期間患者停藥間隔不超過30 d判斷為服藥有持續(xù)性。結(jié)果在2年隨訪期,試驗組和對照組的MPR(%)中位數(shù)分別為50.0(4.0,100.0)和40.0(8.0,100.0)(P=0.92),服藥有持續(xù)性的患者分別為39%和33%,差異無顯著意義(P=0.49)。經(jīng)過校正后,在2年隨訪期,試驗組患者服藥順應性并不比對照組高(OR=1.44,95%CI:0.72~2.86,P=0.30)。結(jié)論阿侖膦酸鈉2周1次口服治療并不能提高骨質(zhì)疏松癥患者藥物治療的順應性和持續(xù)性,還需進一步研究提高服用骨質(zhì)疏松癥藥物患者依從性的方法。
[Abstract]:Objective to study the effect of alendronate interval on compliance of osteoporosis patients. Methods 164 women with osteoporosis were randomly divided into the experimental group (n = 83) treated with alendronate (70 mg / d) and the control group (n = 81) with alendronate (n = 70 mg) once a week. Drug compliance, drug persistence and adverse reactions were observed for two years. According to the drug holding rate and MPRs during the treatment period, the patients' compliance was judged by MPR 鈮，

本文編號：1781616